IP Library Granted Patent US 10,940,158
Granted Patent B2
US 10,940,158 · App. 15/036,855 · Granted Mar 9, 2021

Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,940,158
App. No.
15/036,855
Granted
Mar 9, 2021
Kind
B2
Abstract

The present invention relates to a composition comprising at least one human milk oligosaccharide and/or a precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants or young children born by C-section.

Claims (16)

1. A method for treating necrotizing enterocolitis and/or decreasing incidence of necrotizing enterocolitis in an infant or young child born by C-section, the method comprising administering to the infant or young child born by C-section a composition comprising a mixture of human milk oligosaccharides, the mixture comprising 2′-fucosyllactose (2FL) that is 60 to 70 wt. % of the mixture, an N-acetylated oligosaccharide that is 20 to 30 wt. % of the mixture, and 6′ sialyllactose (6SL) that is 10 to 20 wt. % of the mixture, the N-acetylated oligosaccharide comprising lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) in a ratio LNT:LNnT between 2:1 and 1:1.

2. The method according to claim 1 wherein the infant or young child is a preterm infant born by C-section, and the composition is administered to the preterm infant born by C-section during the first week after birth of the infant.

3. The method according to claim 1 , wherein the mixture further comprises a precursor of human milk oligosaccharide selected from the group consisting of sialic acid, fucose and combinations thereof.

4. The method according to claim 1 wherein the composition is administered in an amount that provides a daily dose of 0.1 to 3 g of the N-acetylated oligosaccharide.

5. The method according to claim 1 wherein the composition is administered in an amount that provides a daily dose of 0.1 to 2 g of the 6 ′ sialyllactose (6SL).

6. The method according to claim 1 wherein the composition is administered in an amount that provides a daily dose of 0.1 to 4 g of the 2′-fucosyllactose (2FL).

7. The method according to claim 1 , wherein the mixture further comprises 3′ sialyllactose (3-SL).

8. The method according to claim 1 , wherein the mixture further comprises a fucosylated oligosaccharide selected from the group consisting of 3-fucosyllactose (3-FL), difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-difucohexaose I, lacto-N-fucohexaose, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose, difucosyllacto-N-hexaose I, difuco-lacto-N-neohexaose, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, tri-fuco-para-Lacto-N-hexaose I and combinations thereof.

9. The method according to claim 1 wherein the mixture further comprises sialic acid.

10. The method according to claim 1 , wherein the composition comprises at least one probiotic in an amount of from 10 3 to 10 12 cfu/g of the composition (dry weight).

11. The method according to claim 1 , wherein the composition is selected from the group consisting of a nutritional composition, a preparation and a food product.

12. The method according to claim 1 , wherein the composition is selected from the group consisting of an infant formula, a starter infant formula, a follow-on infant formula, a baby food, an infant cereal composition, a growing-up milk, a fortifier and a supplement.

13. The method according to claim 1 , wherein the composition is administered to the infant or young child before and/or during the weaning period.

14. The method according to claim 1 , wherein the infant or young child is a preterm infant born by C-section.

15. The method according to claim 1 , wherein the N-acetylated oligosaccharide comprises lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) in a ratio LNT:LNnT between 2:1.2 and 2:1.6.

16. The method according to claim 1 , wherein the N-acetylated oligosaccharide comprises lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) in a ratio LNT:LNnT of 1.3:1.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →